Treatment of active secondary progressive multiple sclerosis with treosulfan

Journal of Neurology

Volumn 254, Issue 7, 2007, Pages 884-889

  Wiendl, H ^a   Kieseier, B C ^c   Weissert, R ^b   Mylius, H A ^e   Pichlmeier, U ^e   Hartung, H P ^c   Melms, A ^b   Kuker, W ^d   Weller, M ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d RADCLIFFE INFIRMARY   (United Kingdom)

^e MEDAC GMBH   (Germany)

Author keywords

Clinical trial; Immunosuppression; Multiple scierosis; Secondary progressive MS; Treosulfan

Indexed keywords

ALKYLATING AGENT; CYTOTOXIC AGENT; TREOSULFAN;

ABDOMINAL PAIN; ADULT; ARTICLE; ATAXIA; CLINICAL TRIAL; DISEASE ACTIVITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; INJECTION SITE REACTION; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PETECHIA; PRIORITY JOURNAL; RESTLESSNESS; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTIGO; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 34547655745     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-006-0459-6     Document Type: Article

References (7)

1. Goffette S, van Pesch V, Vanoverschelde JL, Morandini F, Sindic CJ (2005) Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. J Neurol 252(10):1217-22
2. Weissert R, Wiendl H, Pfrommer H, et al. (2003) Action of treosulfan in myelin-oligodentrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. J Neuroimmunol 144:28-37
3. Sjöö F, Hassan Z, Abedi-Valugerdi M, et al. (2006) Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol 34:115-21
4. McDonald WI, Compston A, Edan G, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-7
5. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907-11
6. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-52
7. Fischer JS, Rudick RA, Cutter GR, Reingold SC (1995) The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 5:244-50